{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"64.6"},{"groupId":"OG001","value":"47.3"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"65"},{"groupId":"OG001","value":"55"}],"units":"Participants"}],"description":"Defined as the percentage of patients who are alive at 18 months after randomization divided by the total number of evaluable patients in each arm. An evaluable patient is defined as any patient who signed informed consent, deemed eligible by central review and received any protocol-defined treatment. 95% confidence interval will be estimated based on standard method. Chi-squared test (or Fisher's exact test if the data in contingency table is sparse) will be used to compare 18 month OS rates among treatment arms. OS within each arm will be summarized by Kaplan-Meier method. Median, 1-year and 2-year rates will be estimated based on Kaplan-Meier curves.","groups":[{"description":"Patients receive 8 cycles of mFOLFIRINOX. One cycle is 14 days. mFOLFIRINOX consists of oxaliplatin, irinotecan, leucovorin and 5-FU. Patients undergo surgery and receive 4 cycles of FOLFOX 4-12 weeks after surgery. FOLFOX consists of oxaliplatin, leucovorin and 5-FU.","id":"OG000","title":"Arm 1 (mFOLFIRINOX + Surgery + FOLFOX)"},{"description":"Patients receive 7 cycles of mFOLFIRINOX. One cycle is 14 days. mFOLFIRINOX consists of oxaliplatin, irinotecan, leucovorin and 5-FU. Patients receive radiation therapy then undergo surgery and receive 4 cycles of FOLFOX 4-12 weeks after surgery. FOLFOX consists of oxaliplatin, leucovorin and 5-FU.","id":"OG001","title":"Arm 2 (mFOLFIRINOX + Radiation + Surgery + FOLFOXx)"}],"paramType":"NUMBER","populationDescription":"Excluded from analysis were 6 patients that withdrew or progressed prior to treatment.","reportingStatus":"POSTED","timeFrame":"18 months","title":"Overall Survival (OS) Rate","type":"PRIMARY","unitOfMeasure":"percentage of patients"}